Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Ces entities : Incyte corporation save search
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
Published: 2022-03-14 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.3%
H: 0.85%
C: -2.08%
new drug treatment fda application ces drug
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
Published: 2022-02-28 (Crawled : 22:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 1.03%
H: 4.76%
C: 0.35%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
financial results ces results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.